

# Inhalation CDMO Industry Research Report 2025

<https://marketpublishers.com/r/ICC4357C1449EN.html>

Date: February 2025

Pages: 132

Price: US\$ 2,950.00 (Single User License)

ID: ICC4357C1449EN

## Abstracts

### Summary

According to APO Research, The global Inhalation CDMO market was valued at US\$ million in 2024 and is anticipated to reach US\$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Inhalation CDMO is estimated to increase from \$ million in 2025 to reach \$ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Inhalation CDMO is estimated to increase from \$ million in 2025 to reach \$ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Inhalation CDMO is estimated to increase from \$ million in 2025 to reach \$ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Inhalation CDMO include Aptar Pharma, Bend Bioscience, Bespak, Catalent, CritiTech, Enteris Biopharma, Experic, HCmed and Hovione, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

### Report Scope

This report aims to provide a comprehensive presentation of the global market for Inhalation CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze

their position in the current marketplace, and make informed business decisions regarding Inhalation CDMO.

The Inhalation CDMO market size, estimations, and forecasts are provided in terms of revenue (\$ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Inhalation CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

### Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

### Inhalation CDMO Segment by Company

Aptar Pharma

Bend Bioscience

Bespak

Catalent

CritiTech

Enteris Biopharma

Experic

HCmed

Hovione

Iconovo

Kindeva

Lonza

Particle Sciences

Proveris

Recipharm

Renejix

Ritedose

Vectura

Sanner

## Inhalation CDMO Segment by Type

Soft Mist Inhalers (SMIs)

Dry Powder Inhalers (DPIs)

Metered Dose Inhalers (MDIs)

Others

## Inhalation CDMO Segment by Application

Commercial

Academic Research

Others

#### Inhalation CDMO Segment by Application

Commercial

Academic Research

Others

#### Inhalation CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

## Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

## Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inhalation CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inhalation CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inhalation CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

## Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Inhalation CDMO companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

## Contents

### 1 PREFACE

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
  - 1.5.1 Secondary Sources
  - 1.5.2 Primary Sources

### 2 MARKET OVERVIEW

- 2.1 Product Definition
- 2.2 Inhalation CDMO by Type
  - 2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
  - 2.2.2 Soft Mist Inhalers (SMIs)
  - 2.2.3 Dry Powder Inhalers (DPIs)
  - 2.2.4 Metered Dose Inhalers (MDIs)
  - 2.2.5 Others
- 2.3 Inhalation CDMO by Application
  - 2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
  - 2.3.2 Commercial
  - 2.3.3 Academic Research
  - 2.3.4 Others
- 2.4 Assumptions and Limitations

### 3 INHALATION CDMO BREAKDOWN DATA BY TYPE

- 3.1 Global Inhalation CDMO Historic Market Size by Type (2020-2025)
- 3.2 Global Inhalation CDMO Forecasted Market Size by Type (2026-2031)

### 4 INHALATION CDMO BREAKDOWN DATA BY APPLICATION

- 4.1 Global Inhalation CDMO Historic Market Size by Application (2020-2025)
- 4.2 Global Inhalation CDMO Forecasted Market Size by Application (2026-2031)

### 5 GLOBAL GROWTH TRENDS

- 5.1 Global Inhalation CDMO Market Perspective (2020-2031)
- 5.2 Global Inhalation CDMO Growth Trends by Region
  - 5.2.1 Global Inhalation CDMO Market Size by Region: 2020 VS 2024 VS 2031
  - 5.2.2 Inhalation CDMO Historic Market Size by Region (2020-2025)
  - 5.2.3 Inhalation CDMO Forecasted Market Size by Region (2026-2031)
- 5.3 Inhalation CDMO Market Dynamics
  - 5.3.1 Inhalation CDMO Industry Trends
  - 5.3.2 Inhalation CDMO Market Drivers
  - 5.3.3 Inhalation CDMO Market Challenges
  - 5.3.4 Inhalation CDMO Market Restraints

## **6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS**

- 6.1 Global Top Inhalation CDMO Players by Revenue
  - 6.1.1 Global Top Inhalation CDMO Players by Revenue (2020-2025)
  - 6.1.2 Global Inhalation CDMO Revenue Market Share by Players (2020-2025)
- 6.2 Global Inhalation CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Inhalation CDMO Head Office and Area Served
- 6.4 Global Inhalation CDMO Players, Product Type & Application
- 6.5 Global Inhalation CDMO Manufacturers Established Date
- 6.6 Global Inhalation CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition

## **7 NORTH AMERICA**

- 7.1 North America Inhalation CDMO Market Size (2020-2031)
- 7.2 North America Inhalation CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 7.3 North America Inhalation CDMO Market Size by Country (2020-2025)
- 7.4 North America Inhalation CDMO Market Size by Country (2026-2031)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico

## **8 EUROPE**

- 8.1 Europe Inhalation CDMO Market Size (2020-2031)

8.2 Europe Inhalation CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

8.3 Europe Inhalation CDMO Market Size by Country (2020-2025)

8.4 Europe Inhalation CDMO Market Size by Country (2026-2031)

8.5 Germany

8.6 France

8.7 U.K.

8.8 Italy

8.9 Spain

8.10 Russia

8.11 Netherlands

8.12 Nordic Countries

## **9 ASIA-PACIFIC**

9.1 Asia-Pacific Inhalation CDMO Market Size (2020-2031)

9.2 Asia-Pacific Inhalation CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Asia-Pacific Inhalation CDMO Market Size by Country (2020-2025)

9.4 Asia-Pacific Inhalation CDMO Market Size by Country (2026-2031)

9.5 China

9.6 Japan

9.7 South Korea

9.8 India

9.9 Australia

9.10 China Taiwan

9.11 Southeast Asia

## **10 SOUTH AMERICA**

10.1 South America Inhalation CDMO Market Size (2020-2031)

10.2 South America Inhalation CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 South America Inhalation CDMO Market Size by Country (2020-2025)

10.4 South America Inhalation CDMO Market Size by Country (2026-2031)

10.5 Brazil

10.6 Argentina

10.7 Chile

10.8 Colombia

10.9 Peru

## **11 MIDDLE EAST & AFRICA**

11.1 Middle East & Africa Inhalation CDMO Market Size (2020-2031)

11.2 Middle East & Africa Inhalation CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

11.3 Middle East & Africa Inhalation CDMO Market Size by Country (2020-2025)

11.4 Middle East & Africa Inhalation CDMO Market Size by Country (2026-2031)

11.5 Saudi Arabia

11.6 Israel

11.7 United Arab Emirates

11.8 Turkey

11.9 Iran

11.10 Egypt

## **12 PLAYERS PROFILED**

12.1 Aptar Pharma

12.1.1 Aptar Pharma Company Information

12.1.2 Aptar Pharma Business Overview

12.1.3 Aptar Pharma Revenue in Inhalation CDMO Business (2020-2025)

12.1.4 Aptar Pharma Inhalation CDMO Product Portfolio

12.1.5 Aptar Pharma Recent Developments

12.2 Bend Bioscience

12.2.1 Bend Bioscience Company Information

12.2.2 Bend Bioscience Business Overview

12.2.3 Bend Bioscience Revenue in Inhalation CDMO Business (2020-2025)

12.2.4 Bend Bioscience Inhalation CDMO Product Portfolio

12.2.5 Bend Bioscience Recent Developments

12.3 Bepak

12.3.1 Bepak Company Information

12.3.2 Bepak Business Overview

12.3.3 Bepak Revenue in Inhalation CDMO Business (2020-2025)

12.3.4 Bepak Inhalation CDMO Product Portfolio

12.3.5 Bepak Recent Developments

12.4 Catalent

12.4.1 Catalent Company Information

12.4.2 Catalent Business Overview

12.4.3 Catalent Revenue in Inhalation CDMO Business (2020-2025)

- 12.4.4 Catalent Inhalation CDMO Product Portfolio
- 12.4.5 Catalent Recent Developments
- 12.5 CritiTech
  - 12.5.1 CritiTech Company Information
  - 12.5.2 CritiTech Business Overview
  - 12.5.3 CritiTech Revenue in Inhalation CDMO Business (2020-2025)
  - 12.5.4 CritiTech Inhalation CDMO Product Portfolio
  - 12.5.5 CritiTech Recent Developments
- 12.6 Enteris Biopharma
  - 12.6.1 Enteris Biopharma Company Information
  - 12.6.2 Enteris Biopharma Business Overview
  - 12.6.3 Enteris Biopharma Revenue in Inhalation CDMO Business (2020-2025)
  - 12.6.4 Enteris Biopharma Inhalation CDMO Product Portfolio
  - 12.6.5 Enteris Biopharma Recent Developments
- 12.7 Experic
  - 12.7.1 Experic Company Information
  - 12.7.2 Experic Business Overview
  - 12.7.3 Experic Revenue in Inhalation CDMO Business (2020-2025)
  - 12.7.4 Experic Inhalation CDMO Product Portfolio
  - 12.7.5 Experic Recent Developments
- 12.8 HCmed
  - 12.8.1 HCmed Company Information
  - 12.8.2 HCmed Business Overview
  - 12.8.3 HCmed Revenue in Inhalation CDMO Business (2020-2025)
  - 12.8.4 HCmed Inhalation CDMO Product Portfolio
  - 12.8.5 HCmed Recent Developments
- 12.9 Hovione
  - 12.9.1 Hovione Company Information
  - 12.9.2 Hovione Business Overview
  - 12.9.3 Hovione Revenue in Inhalation CDMO Business (2020-2025)
  - 12.9.4 Hovione Inhalation CDMO Product Portfolio
  - 12.9.5 Hovione Recent Developments
- 12.10 Iconovo
  - 12.10.1 Iconovo Company Information
  - 12.10.2 Iconovo Business Overview
  - 12.10.3 Iconovo Revenue in Inhalation CDMO Business (2020-2025)
  - 12.10.4 Iconovo Inhalation CDMO Product Portfolio
  - 12.10.5 Iconovo Recent Developments
- 12.11 Kindeva

- 12.11.1 Kindeva Company Information
- 12.11.2 Kindeva Business Overview
- 12.11.3 Kindeva Revenue in Inhalation CDMO Business (2020-2025)
- 12.11.4 Kindeva Inhalation CDMO Product Portfolio
- 12.11.5 Kindeva Recent Developments
- 12.12 Lonza
  - 12.12.1 Lonza Company Information
  - 12.12.2 Lonza Business Overview
  - 12.12.3 Lonza Revenue in Inhalation CDMO Business (2020-2025)
  - 12.12.4 Lonza Inhalation CDMO Product Portfolio
  - 12.12.5 Lonza Recent Developments
- 12.13 Particle Sciences
  - 12.13.1 Particle Sciences Company Information
  - 12.13.2 Particle Sciences Business Overview
  - 12.13.3 Particle Sciences Revenue in Inhalation CDMO Business (2020-2025)
  - 12.13.4 Particle Sciences Inhalation CDMO Product Portfolio
  - 12.13.5 Particle Sciences Recent Developments
- 12.14 Proveris
  - 12.14.1 Proveris Company Information
  - 12.14.2 Proveris Business Overview
  - 12.14.3 Proveris Revenue in Inhalation CDMO Business (2020-2025)
  - 12.14.4 Proveris Inhalation CDMO Product Portfolio
  - 12.14.5 Proveris Recent Developments
- 12.15 Recipharm
  - 12.15.1 Recipharm Company Information
  - 12.15.2 Recipharm Business Overview
  - 12.15.3 Recipharm Revenue in Inhalation CDMO Business (2020-2025)
  - 12.15.4 Recipharm Inhalation CDMO Product Portfolio
  - 12.15.5 Recipharm Recent Developments
- 12.16 Renejix
  - 12.16.1 Renejix Company Information
  - 12.16.2 Renejix Business Overview
  - 12.16.3 Renejix Revenue in Inhalation CDMO Business (2020-2025)
  - 12.16.4 Renejix Inhalation CDMO Product Portfolio
  - 12.16.5 Renejix Recent Developments
- 12.17 Ritedose
  - 12.17.1 Ritedose Company Information
  - 12.17.2 Ritedose Business Overview
  - 12.17.3 Ritedose Revenue in Inhalation CDMO Business (2020-2025)

12.17.4 Ritedose Inhalation CDMO Product Portfolio

12.17.5 Ritedose Recent Developments

12.18 Vectura

12.18.1 Vectura Company Information

12.18.2 Vectura Business Overview

12.18.3 Vectura Revenue in Inhalation CDMO Business (2020-2025)

12.18.4 Vectura Inhalation CDMO Product Portfolio

12.18.5 Vectura Recent Developments

12.19 Sanner

12.19.1 Sanner Company Information

12.19.2 Sanner Business Overview

12.19.3 Sanner Revenue in Inhalation CDMO Business (2020-2025)

12.19.4 Sanner Inhalation CDMO Product Portfolio

12.19.5 Sanner Recent Developments

## **13 REPORT CONCLUSION**

## **14 DISCLAIMER**

## I would like to order

Product name: Inhalation CDMO Industry Research Report 2025

Product link: <https://marketpublishers.com/r/ICC4357C1449EN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ICC4357C1449EN.html>